BSD Medical Announces Shipment of Third BSD-2000 Hyperthermia System to Taiwan Distributor

  BSD Medical Announces Shipment of Third BSD-2000 Hyperthermia System to   Taiwan Distributor  BSD has Sold Three BSD-2000 Hyperthermia Systems to Linden Bioscience since Linden Obtained Taiwan Food and Drug Administration (TFDA) Marketing Approval in February 2014  Business Wire  SALT LAKE CITY -- June 2, 2014  BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD has shipped three of four BSD-2000 Hyperthermia Systems (BSD-2000) ordered by its exclusive Taiwan distributor, Linden Bioscience Co., Ltd (Linden). Linden is a leading distributor of sophisticated medical devices in Taiwan. The Company shipped the first two BSD-2000 systems to Linden in February 2014. BSD plans to ship the fourth BSD-2000 to Linden by August 31, 2014.  “We are pleased to sell another BSD-2000 system to Linden,” stated Sam Maravich, Vice President of International Sales and Marketing of BSD Medical. “Linden is working with key prestigious Taiwanese hospitals for installation of the first BSD-2000 systems. Linden is also working diligently with notable key opinion leaders in Taiwan to further expand awareness of the clinical benefits of the BSD-2000,” concluded Mr. Maravich.  There is a substantial marketing opportunity for BSD's products in Taiwan, which is one of the most advanced medical device markets in Asia. The total medical device market in Taiwan is estimated to be approximately $1.6 billion.  About the BSD-2000 Hyperthermia System  The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.  About BSD Medical Corporation  BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.  This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.  Contact:  BSD Medical Corporation William Barth, 801-972-5555 Fax: 801-972-5930 investor@bsdmc.com  
Press spacebar to pause and continue. Press esc to stop.